Table 1 High-risk criteria
From: Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
Evidence grade I: | Infants born from 32 weeks of gestation or earlier to 12 months at the beginning of RSV season. |
Evidence grade I: | Infants and children younger than 24 months with CLD who required medical therapy (supplemental oxygen and/or drugs). |
Evidence grade I: | 24 months old or younger children receiving medication to control hemodybamically significant heart disease or diagnosed with moderate to severe pulmonary hypertension or diagnosed with cyanotic heart disease. |
Evidence grade III: | Infants, born at 32 to less 35 weeks of gestation, who are 12 months old, or younger, at the start of RSV season with at least two of the following risk factors: low weight at birth (<2.5 Kg), exposure to environmental air pollutants or tobacco smoke, lack of breast-feed, twin birth, chest malformation, hematologic diseases, cystic fibrosis, school-aged siblings, congenital abnormalities of the airways, cancer, severe neuromuscular diseases, immunodefiency or living where the access to a hospital is difficult. |